In a welcome move, Eli Lilly saw its Relative Strength Rating rise from 61 to 71 on Thursday.
This exclusive rating from Investor's Business Daily tracks price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
History shows that the best stocks typically have an 80 or better RS Rating as they begin their largest runs. See if Eli Lilly can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
Eli Lilly is building a consolidation with a 972.53 entry. See if it can clear the breakout price in volume at least 40% higher than normal.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 86% to 1,080%. Revenue rose from 20% to 45%.
The company holds the No. 1 rank among its peers in the Medical-Diversified industry group. Abbott Laboratories and AstraZeneca ADR are also among the group's highest-rated stocks.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
